2018

 

  1. Carlsson J, Davidsson S, Fridfeldt J, Giunchi F, Fiano V, Grasso C, Zelic R, Richiardi L, Andrén O, Pettersson A, Fiorentino M, Akre O. Quantity and quality of nucleic acids extracted from archival formalin fixed paraffin embedded prostate biopsies. BMC Med Res Methodol. 2018 Dec 5;18(1):161. Sammanfattning
  2. Li W, Middha M, Bicak M, Sjoberg DD, Vertosick E, Dahlin A, Häggström C, Hallmans G, Rönn AC, Stattin P, Melander O, Ulmert D, Lilja H, Klein RJ. Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival. Eur Urol. 2018 Dec;74(6):710-719. Sammanfattning
  3. Matejcic M, Saunders EJ, Dadaev T, Brook MN, Wang K, Sheng X, Olama AAA, Schumacher FR, Ingles SA, Govindasami K, Benlloch S, Berndt SI, Albanes D, Koutros S, Muir K, Stevens VL, Gapstur SM, Tangen CM, Batra J, Clements J, Gronberg H, Pashayan N, Schleutker J, Wolk A, West C, Mucci L, Kraft P, Cancel-Tassin G, Sorensen KD, Maehle L, Grindedal EM, Strom SS, Neal DE, Hamdy FC, Donovan JL, Travis RC, Hamilton RJ, Rosenstein B, Lu YJ, Giles GG, Kibel AS, Vega A, Bensen JT, Kogevinas M, Penney KL, Park JY, Stanford JL, Cybulski C, Nordestgaard BG, Brenner H, Maier C, Kim J, Teixeira MR, Neuhausen SL, De Ruyck K, Razack A, Newcomb LF, Lessel D, Kaneva R, Usmani N, Claessens F, Townsend PA, Dominguez MG, Roobol MJ, Menegaux F, Khaw KT, Cannon-Albright LA, Pandha H, Thibodeau SN, Schaid DJ; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Wiklund F, Chanock SJ, Easton DF, Eeles RA, Kote-Jarai Z, Conti DV, Haiman CA. Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat Commun. 2018 Nov 5;9(1):4616. Sammanfattning
  4. Häggström C, Van Hemelrijck M, Garmo H, Robinson D, Stattin P, Rowley M, Coolen ACC, Holmberg L. Heterogeneity in risk of prostate cancer: A Swedish population-based cohort study of competing risks and type 2 diabetes mellitus, Int J Cancer. M2018 Oct 15;143(8):1868-1875. Sammanfattning
  5. Nugin H, Folkvaljon Y, Damber JE, Adolfsson J, Robinson D, Stattin P. Work-up and treatment of prostate cancer before and after publication of the first national guidelines on prostate cancer care in Sweden. Scand J Urol. 2018 Aug;52(4):277-284. Sammanfattning
  6. Stattin P, Sandin F, Loeb S, Robinson D, Franck Lissbrant I, Lambe M. Public online reporting from a nationwide population-based clinical prostate cancer register, BJU Int. 2018 Jul;122(1):8-10. Sammanfattning
  7. Zelic R, Zugna D, Bottai M,  Andrén O, Fridfeldt J, Carlsson J, Davidsson S, Fiano V, Fiorentino M, Giunchi F, Grasso C, Lianas L, Mascia C, Molinaro L, Zanetti G, Richiardi L, Pettersson A, Akre O. Estimation of Relative and Absolute Risks in a Competing-Risks Setting Using a Nested Case-Control Study Design: Example From the ProMort Study. Am J Epidemiol. 2019 Jun 1;188. Sammanfattning
  8. Jansson F, Drevin L, Frisell T, Stattin P, Bratt O, Akre O. Concordance of Non-Low-Risk Disease Among Pairs of Brothers With Prostate Cancer, J Clin Oncol. 2018 Jun 20;36(18):1847-1852. Sammanfattning
  9. Katarina Tomic. Data quality in the National Prostate Cancer Register (NPCR) of Sweden. Umeå University Dissertations New Series No 1945. ISSN 0346-6612 Fulltext
  10. Tomic K, Ventimiglia E, Robinson D, Häggström C, Lambe M, Stattin P. Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study, Int J Cancer. 2018 Jun 15;142(12):2478-2484. Sammanfattning
  11. Arthur R, Williams R, Garmo H, Holmberg L, Stattin P, Malmström H, Lambe M, Hammar N, Walldius G, Robinsson D, Jungner I, Van Hemelrijck M. Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study, Int J Cancer. 2018 Jun 1;142(11):2254-2262. Sammanfattning
  12. FitzGerald LM, Zhao S, Leonardson A, Geybels MS, Kolb S, Lin DW, Wright JL, Eeles R, Kote-Jarai Z, Govindasami K, Giles GG, Southey MC, Schleutker J, Tammela TL, Sipeky C, Penney KL, Stampfer MJ, Gronberg H, Wiklund F, Stattin P, Hugosson J, Karyadi DM, Ostrander EA, Feng Z, Stanford JL. Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer Prostatic Dis. 2018 Jun;21(2):228-237. Sammanfattning
  13. Beckmann K, Garmo H, Adolfsson J, Bosco C, Johansson E, Robinson D, Holmberg L, Stattin P, Van Hemelrijck M.  Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer. Eur Urol. 2019 Apr;75(4):676-683. Sammanfattning 
  14. Russell B, Garmo H, Beckmann K, Stattin P, Adolfsson J, Van Hemelrijck M. A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0, PLoS One. 2018 Apr 12;13(4):e0195690. Sammanfattning
  15. Franck Lissbrant I, Ventimiglia E, Robinson D, Törnblom M, Hjälm-Eriksson M, Lambe M, Folkvaljon Y, Stattin P. Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden, Scand J Urol. 2018 Apr;52(2):143-150. Sammanfattning
  16. Robinson D, Garmo H, Lissbrant IF, Widmark A, Pettersson A, Gunnlaugsson A, Adolfsson J, Bratt O, Nilsson P, Stattin P. Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study, Eur Urol. 2018 Apr;73(4):502-511. Sammanfattning
  17. Crawley D, Garmo H, Rudman S, Stattin P, Zethelius B, Armes J, Holmberg L, Adolfsson J, Van Hemelrijck M.  Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study. BMJ Open. 2018 Mar 16;8(3):e020787. Sammanfattning
  18. Gnanapragasam VJ, Bratt O, Muir K, Lee LS, Huang HH, Stattin P, Lophatananon A. The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study, BMC Med. 2018 Feb 28;16(1):31. Sammanfattning
  19. Crawley D, Garmo H, Rudman S, Stattin P, Zethelius B, Holmberg L, Adolfsson J, Van Hemelrijck M. Association between Type 2 diabetes, curative treatment and survival in men with intermediate and high risk localised prostate cancer, BJU Int. 2018 Feb;121(2):209-216. Sammanfattning
  20. Ventimiglia E, Folkvaljon Y, Carlsson S, Bratt O, Montorsi F, Volz D, Akre O, Johansson E, Stattin P. Nationwide, population-based study of post radical prostatectomy urinary incontinence correction surgery, J Surg Oncol. 2018 Feb;117(2):321-327. Sammanfattning
  21. Bosco C, Wong C, Garmo H, Crawley D, Holmberg L, Hammar N, Adolfsson J, Stattin P, Van Hemelrijck M. Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists, BJU Int. 2018 Feb;121(2):260-267. Sammanfattning
  22. Stattin P, Franck Lissbrant I. Diagnosspecifika översikter är viktiga vertyg för cancervården, Lakartidningen. 2018 Jan 9;115. Sammanfattning
  23. Lycken M, Drevin L, Garmo H, Stattin P, Adolfsson J, Lissbrant IF, Holmberg L, Bill-Axelson A. The use of palliative medications before death from prostate cancer: Swedish population-based study with a comparative overview of European data, Eur J Cancer. 2018 Jan;88:101-108. Sammanfattning